COVID-19 Resources for CRRT Treatment

CRRT is preferred treatment modality for COVID-19 patients with AKI

To continue supporting our physicians and nurses who are on the front lines of managing the influx of critically ill patients, many of whom will develop acute kidney injury or experience renal failure during this pandemic, we have consolidated support resources to help you with providing these patients Continuous Renal Replacement Therapy.

The Role of CRRT in the Fight

15-40%

of patients with COVID-19 who are admitted to the ICU have AKI requiring RRT.1-3 There is some evidence that COVID-19 interferes with kidney function itself.1

60-80%

is the mortality rate seen in patients with combined respiratory failure and AKI, indicating the consequences of AKI in mechanically ventilated patients is significant (independent mortality of AKI in the ICU is 30-50%).4

Resource Sections

Go directly to more information on the following:

ASN Logo Slider

Treatment Guidelines

"Acute kidney injury (AKI) requiring acute renal replacement therapy (RRT) occurs in approximately 15% of all ICU admissions, but this rate is often increased greatly in the setting of severe respiratory failure and acute respiratory distress syndrome (ARDS)."

- American Society of Nephrology

Recommendations on the care of hospitalized patients with COVID-19 and kidney failure requiring renal replacement therapy

View ASN Guidelines
Dr. Mary Gellens Slider

"Now, more than ever, Continuous Renal Replacement Therapy is a critical therapy to be used for patients with AKI requiring renal replacement therapy and especially for those patients who are hemodynamically unstable. It has been reported in various countries that a subset of patients with COVID-19 will become severely ill, with a sepsis like syndrome and multiorgan failure, including acute kidney injury. In these critical cases, CRRT may be a life sustaining and life saving therapy."

- Mary Gellens, MD

Senior Medical Director Baxter Healthcare Corporation

DrNeyra_thumbnail

In times of uncertainty, the ability to learn and be proactive makes a huge difference. Our understanding of SARS-CoV-2 prevention and treatment evolves day by day. The clinical characteristics of acute kidney injury (AKI) are heterogeneous and its incidence is reported in up to 25% of patients, some of them requiring renal replacement therapy (RRT). Therefore, preparedness is of utmost importance to maximize our capacity for the provision of RRT. Timely initiation, optimal fluid management and protocolized care with consideration for minimizing healthcare provider exposure should be carefully evaluated.

– Javier A. Neyra, MD, MSCS, FASN

Assistant Professor, Internal Medicine/Nephrology/Bone and Mineral Metabolism Director, Acute Care Nephrology & CRRT Program University of Kentucky Medical Center, Lexington, Kentucky

Kidney_international_logo_thumbnail

The current treatment of COVID-19 with AKI includes general and supportive management and kidney replacement therapy. There is no effective antiviral therapy available at present.

- The Novel Coronavirus 2019 epidemic and kidneys.

Kidney International (2020) Article in press.

adqi_thumbnail

The consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup has been published. The report consists of five work groups addressing: pathophysiology and effects of treatments on the kidney; epidemiology and diagnosis; prevention and management; RRT, particularly under conditions of increased demand (surge); and the use of other forms of extracorporeal blood purification (EBP) for patients with COVID-19 with or without AKI.

-COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup  

Read the report

Products With FDA Emergency Use Authorization

Oxiris_thumbnail_covidpage

OXIRIS 3-in-1 Filter

prismaflex_thumbnail_covidpage

PRISMAFLEX ST Filter Set

Regiocit_thumbnail_covidpage

REGIOCIT Replacement Solution

hf20_thumbnail_covidpage

PRISMAFLEX HF20 Filter Set

Video Resources

CRRT: Pre and Post Replacement Solutions - A Guide to Understanding, Presentation

Therapy Videos

Prismax_thumbnail_trainingvideos

PRISMAX Training Videos

prismaflex_thumbnail_covidpage

PRISMAFLEX Training Videos

Tena-Basic-Principles-CRRT_thumbnail.jpg

BCCI Video Presentation: Principles of CRRT

Neyra-COVID-AKI-learnings_thumbnail.jpg

BCCI WEBINAR: COVID-19 and AKI: What Has Been Learned?

COVID-19-CRRT-AKI-Webinar_Barbara-McClean_3.png

BCCI WEBINAR: COVID-19: The Role of CRRT in AKI


PDF Resources

Reimbursement Coding for CRRT and RRT

Download

Therapy Modalities, Comparisons, and Considerations

Download

KDIGO Guidelines or Quick Reference

Download

PRISMAFLEX/PRISMAX Safety Alert Regarding Modifications to Set-up

Download

PRISMAFLEX/PRISMAX Systems Cleaning for SARS-CoV-2

Download

PRISMAFLEX Operator’s Manual

Download

PRISMAX Operator’s Manual

Download

Baxter Help is Available 24/7

PRISMAFLEX and PRISMAX machines

Clinical Support Help-line

MD and PharmD on call at all times to help answer your questions and/or help you troubleshoot step-by-step.

888-404-ICON (4266)

Technical Support

If you need ordering or logistics support, call
888-229-0001 or online

PRISMAFLEX Rentals

For immediate rental needs, call customer service at:
800-352-1221

U.S. Medical Information

For product questions or complaints, call
888-736-2543 Option 2

Stay Up-to-Date on the Latest News with Our Healthcare Partners

CDC Logo

Center for Disease Control and Prevention

The Society of Critical Care Medicine logo

The Society of Critical Care Medicine

AACN logo

American Association of Critical-Care Nurses (AACN)

ASN logo

American Society of Nephrology (ASN)

CRRT Online logo

CRRTOnline.com

Indications and Important Risk Information

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For the safe and proper use of the products mentioned herein, refer to the appropriate Instructions for Use or Operator's Manual.


PHOXILLUM and PRISMASOL Renal Replacement Solution 

Indications

PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances

Important Risk Information

  • PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products.
  • PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure.
  • PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.
  • PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly.
  • The following adverse reactions have been identified during post-approval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL: Metabolic acidosis, hypotension, acid-based disorders, electrolyte imbalances including calcium ionized increased, hyperphosphatemia, hypophosphatemia, fluid imbalance.

 

For more information, please see Full Prescribing Information for PRISMASOL and PHOXILLUM solutions or visit baxterpi.com.